Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Orange Book Patents
Across 1 drug with upcoming expirations
Activity
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Regulatory
Banthine — BANTHINE
Application NDA007390 (NDA)
Pro-Banthine — PRO-BANTHINE
Application NDA008843 (NDA)
Furoxone — FUROXONE
Application NDA011323 (NDA)
Pro-Banthine — PRO-BANTHINE
Application NDA008732 (NDA)
Furoxone — FUROXONE
Application NDA011270 (NDA)
Actin-N — ACTIN-N
Application NDA017343 (NDA)
Actin-N — FURACIN
Application NDA005795 (NDA)
Ethmozine — ETHMOZINE
Application NDA019753 (NDA)
Supprelin La — SUPPRELIN
Application NDA019836 (NDA)
Supprelin La — VANTAS
Application NDA021732 (NDA)
Supprelin La — SUPPRELIN LA
Application NDA022058 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)